Zacks.com on MSN9h
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...
PMLive12h
Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study
The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...
PharmExec15h
Phase III Trial Data Show Uplizna Significantly Improves Symptoms of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...